Sentinel European Node Trial (SENT)

3-year results of sentinel node biopsy in oral cancer

C. Schilling, S. J. Stoeckli, S. K. Haerle, M. A. Broglie, G. F. Huber, Jens Ahm Sørensen, V. Bakholdt, A. Krogdahl, C. von Buchwald, A. Bilde, L. R. Sebbesen, E. Odell, B. Gurney, M. O'Doherty, R. de Bree, E. Bloemena, G. B. Flach, P. M. Villarreal, M. F. F. Forcelledo, L. M. J. Gutierrez & 24 andre J. A. Amezaga, L. Barbier, J. Santamaria-Zuazua, A. Moreira, M. Jacome, M. G. Vigili, S. Rahimi, G. Tartaglione, G. Lawson, M. C. Nollevaux, C. Grandi, D. Donner, E. Bragantini, D. Dequanter, P. Lothaire, T. Poli, E. M. Silini, E. Sesenna, G. Dolivet, R. Mastronicola, A. Leroux, I. Sassoon, P. Sloan, M. McGurk

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Purpose: Optimum management of the N0 neck is unresolved in oral cancer. Sentinel node biopsy (SNB) can reliably detect microscopic lymph node metastasis. The object of this study was to establish whether the technique was both reliable in staging the N0 neck and a safe oncological procedure in patients with early-stage oral squamous cell carcinoma. Methods: An European Organisation for Research and Treatment of Cancer-approved prospective, observational study commenced in 2005. Fourteen European centres recruited 415 patients with radiologically staged T1-T2N0 squamous cell carcinoma. SNB was undertaken with an average of 3.2 nodes removed per patient. Patients were excluded if the sentinel node (SN) could not be identified. A positive SN led to a neck dissection within 3 weeks. Analysis was performed at 3-year follow-up. Results: An SN was found in 99.5% of cases. Positive SNs were found in 23% (94 in 415). A false-negative result occurred in 14% (15 in 109) of patients, of whom eight were subsequently rescued by salvage therapy. Recurrence after a positive SNB and subsequent neck dissection occurred in 22 patients, of which 16 (73%) were in the neck and just six patients were rescued. Only minor complications (3%) were reported following SNB. Disease-specific survival was 94%. The sensitivity of SNB was 86% and the negative predictive value 95%. Conclusion: These data show that SNB is a reliable and safe oncological technique for staging the clinically N0 neck in patients with T1 and T2 oral cancer. EORTC Protocol 24021: Sentinel Node Biopsy in the Management of Oral and Oropharyngeal Squamous Cell Carcinoma. (C) 2015 Published by Elsevier Ltd.
OriginalsprogEngelsk
TidsskriftEuropean Journal of Cancer
Vol/bind51
Udgave nummer18
Sider (fra-til)2777-2784
ISSN0959-8049
DOI
StatusUdgivet - 2015

Emneord

  • Oral Cancer Sentinel lymph node biopsy Metastasis Recurrence Micrometastasis Lymphoscintigraphy SQUAMOUS-CELL CARCINOMA LYMPH-NODE NECK DISSECTION MULTICENTER TRIAL HEAD METASTASES SURVIVAL CAVITY METAANALYSIS IMPACT

Citer dette

Schilling, C., Stoeckli, S. J., Haerle, S. K., Broglie, M. A., Huber, G. F., Sørensen, J. A., ... McGurk, M. (2015). Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. European Journal of Cancer, 51(18), 2777-2784. https://doi.org/10.1016/j.ejca.2015.08.023
Schilling, C. ; Stoeckli, S. J. ; Haerle, S. K. ; Broglie, M. A. ; Huber, G. F. ; Sørensen, Jens Ahm ; Bakholdt, V. ; Krogdahl, A. ; von Buchwald, C. ; Bilde, A. ; Sebbesen, L. R. ; Odell, E. ; Gurney, B. ; O'Doherty, M. ; de Bree, R. ; Bloemena, E. ; Flach, G. B. ; Villarreal, P. M. ; Forcelledo, M. F. F. ; Gutierrez, L. M. J. ; Amezaga, J. A. ; Barbier, L. ; Santamaria-Zuazua, J. ; Moreira, A. ; Jacome, M. ; Vigili, M. G. ; Rahimi, S. ; Tartaglione, G. ; Lawson, G. ; Nollevaux, M. C. ; Grandi, C. ; Donner, D. ; Bragantini, E. ; Dequanter, D. ; Lothaire, P. ; Poli, T. ; Silini, E. M. ; Sesenna, E. ; Dolivet, G. ; Mastronicola, R. ; Leroux, A. ; Sassoon, I. ; Sloan, P. ; McGurk, M. / Sentinel European Node Trial (SENT) : 3-year results of sentinel node biopsy in oral cancer. I: European Journal of Cancer. 2015 ; Bind 51, Nr. 18. s. 2777-2784.
@article{60d9cc16dd2548559406934160ff8ccb,
title = "Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer",
abstract = "Purpose: Optimum management of the N0 neck is unresolved in oral cancer. Sentinel node biopsy (SNB) can reliably detect microscopic lymph node metastasis. The object of this study was to establish whether the technique was both reliable in staging the N0 neck and a safe oncological procedure in patients with early-stage oral squamous cell carcinoma. Methods: An European Organisation for Research and Treatment of Cancer-approved prospective, observational study commenced in 2005. Fourteen European centres recruited 415 patients with radiologically staged T1-T2N0 squamous cell carcinoma. SNB was undertaken with an average of 3.2 nodes removed per patient. Patients were excluded if the sentinel node (SN) could not be identified. A positive SN led to a neck dissection within 3 weeks. Analysis was performed at 3-year follow-up. Results: An SN was found in 99.5{\%} of cases. Positive SNs were found in 23{\%} (94 in 415). A false-negative result occurred in 14{\%} (15 in 109) of patients, of whom eight were subsequently rescued by salvage therapy. Recurrence after a positive SNB and subsequent neck dissection occurred in 22 patients, of which 16 (73{\%}) were in the neck and just six patients were rescued. Only minor complications (3{\%}) were reported following SNB. Disease-specific survival was 94{\%}. The sensitivity of SNB was 86{\%} and the negative predictive value 95{\%}. Conclusion: These data show that SNB is a reliable and safe oncological technique for staging the clinically N0 neck in patients with T1 and T2 oral cancer. EORTC Protocol 24021: Sentinel Node Biopsy in the Management of Oral and Oropharyngeal Squamous Cell Carcinoma. (C) 2015 Published by Elsevier Ltd.",
keywords = "Oral Cancer Sentinel lymph node biopsy Metastasis Recurrence Micrometastasis Lymphoscintigraphy SQUAMOUS-CELL CARCINOMA LYMPH-NODE NECK DISSECTION MULTICENTER TRIAL HEAD METASTASES SURVIVAL CAVITY METAANALYSIS IMPACT",
author = "C. Schilling and Stoeckli, {S. J.} and Haerle, {S. K.} and Broglie, {M. A.} and Huber, {G. F.} and S{\o}rensen, {Jens Ahm} and V. Bakholdt and A. Krogdahl and {von Buchwald}, C. and A. Bilde and Sebbesen, {L. R.} and E. Odell and B. Gurney and M. O'Doherty and {de Bree}, R. and E. Bloemena and Flach, {G. B.} and Villarreal, {P. M.} and Forcelledo, {M. F. F.} and Gutierrez, {L. M. J.} and Amezaga, {J. A.} and L. Barbier and J. Santamaria-Zuazua and A. Moreira and M. Jacome and Vigili, {M. G.} and S. Rahimi and G. Tartaglione and G. Lawson and Nollevaux, {M. C.} and C. Grandi and D. Donner and E. Bragantini and D. Dequanter and P. Lothaire and T. Poli and Silini, {E. M.} and E. Sesenna and G. Dolivet and R. Mastronicola and A. Leroux and I. Sassoon and P. Sloan and M. McGurk",
note = "0 26597442",
year = "2015",
doi = "10.1016/j.ejca.2015.08.023",
language = "English",
volume = "51",
pages = "2777--2784",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon",
number = "18",

}

Schilling, C, Stoeckli, SJ, Haerle, SK, Broglie, MA, Huber, GF, Sørensen, JA, Bakholdt, V, Krogdahl, A, von Buchwald, C, Bilde, A, Sebbesen, LR, Odell, E, Gurney, B, O'Doherty, M, de Bree, R, Bloemena, E, Flach, GB, Villarreal, PM, Forcelledo, MFF, Gutierrez, LMJ, Amezaga, JA, Barbier, L, Santamaria-Zuazua, J, Moreira, A, Jacome, M, Vigili, MG, Rahimi, S, Tartaglione, G, Lawson, G, Nollevaux, MC, Grandi, C, Donner, D, Bragantini, E, Dequanter, D, Lothaire, P, Poli, T, Silini, EM, Sesenna, E, Dolivet, G, Mastronicola, R, Leroux, A, Sassoon, I, Sloan, P & McGurk, M 2015, 'Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer', European Journal of Cancer, bind 51, nr. 18, s. 2777-2784. https://doi.org/10.1016/j.ejca.2015.08.023

Sentinel European Node Trial (SENT) : 3-year results of sentinel node biopsy in oral cancer. / Schilling, C.; Stoeckli, S. J.; Haerle, S. K.; Broglie, M. A.; Huber, G. F.; Sørensen, Jens Ahm; Bakholdt, V.; Krogdahl, A.; von Buchwald, C.; Bilde, A.; Sebbesen, L. R.; Odell, E.; Gurney, B.; O'Doherty, M.; de Bree, R.; Bloemena, E.; Flach, G. B.; Villarreal, P. M.; Forcelledo, M. F. F.; Gutierrez, L. M. J.; Amezaga, J. A.; Barbier, L.; Santamaria-Zuazua, J.; Moreira, A.; Jacome, M.; Vigili, M. G.; Rahimi, S.; Tartaglione, G.; Lawson, G.; Nollevaux, M. C.; Grandi, C.; Donner, D.; Bragantini, E.; Dequanter, D.; Lothaire, P.; Poli, T.; Silini, E. M.; Sesenna, E.; Dolivet, G.; Mastronicola, R.; Leroux, A.; Sassoon, I.; Sloan, P.; McGurk, M.

I: European Journal of Cancer, Bind 51, Nr. 18, 2015, s. 2777-2784.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Sentinel European Node Trial (SENT)

T2 - 3-year results of sentinel node biopsy in oral cancer

AU - Schilling, C.

AU - Stoeckli, S. J.

AU - Haerle, S. K.

AU - Broglie, M. A.

AU - Huber, G. F.

AU - Sørensen, Jens Ahm

AU - Bakholdt, V.

AU - Krogdahl, A.

AU - von Buchwald, C.

AU - Bilde, A.

AU - Sebbesen, L. R.

AU - Odell, E.

AU - Gurney, B.

AU - O'Doherty, M.

AU - de Bree, R.

AU - Bloemena, E.

AU - Flach, G. B.

AU - Villarreal, P. M.

AU - Forcelledo, M. F. F.

AU - Gutierrez, L. M. J.

AU - Amezaga, J. A.

AU - Barbier, L.

AU - Santamaria-Zuazua, J.

AU - Moreira, A.

AU - Jacome, M.

AU - Vigili, M. G.

AU - Rahimi, S.

AU - Tartaglione, G.

AU - Lawson, G.

AU - Nollevaux, M. C.

AU - Grandi, C.

AU - Donner, D.

AU - Bragantini, E.

AU - Dequanter, D.

AU - Lothaire, P.

AU - Poli, T.

AU - Silini, E. M.

AU - Sesenna, E.

AU - Dolivet, G.

AU - Mastronicola, R.

AU - Leroux, A.

AU - Sassoon, I.

AU - Sloan, P.

AU - McGurk, M.

N1 - 0 26597442

PY - 2015

Y1 - 2015

N2 - Purpose: Optimum management of the N0 neck is unresolved in oral cancer. Sentinel node biopsy (SNB) can reliably detect microscopic lymph node metastasis. The object of this study was to establish whether the technique was both reliable in staging the N0 neck and a safe oncological procedure in patients with early-stage oral squamous cell carcinoma. Methods: An European Organisation for Research and Treatment of Cancer-approved prospective, observational study commenced in 2005. Fourteen European centres recruited 415 patients with radiologically staged T1-T2N0 squamous cell carcinoma. SNB was undertaken with an average of 3.2 nodes removed per patient. Patients were excluded if the sentinel node (SN) could not be identified. A positive SN led to a neck dissection within 3 weeks. Analysis was performed at 3-year follow-up. Results: An SN was found in 99.5% of cases. Positive SNs were found in 23% (94 in 415). A false-negative result occurred in 14% (15 in 109) of patients, of whom eight were subsequently rescued by salvage therapy. Recurrence after a positive SNB and subsequent neck dissection occurred in 22 patients, of which 16 (73%) were in the neck and just six patients were rescued. Only minor complications (3%) were reported following SNB. Disease-specific survival was 94%. The sensitivity of SNB was 86% and the negative predictive value 95%. Conclusion: These data show that SNB is a reliable and safe oncological technique for staging the clinically N0 neck in patients with T1 and T2 oral cancer. EORTC Protocol 24021: Sentinel Node Biopsy in the Management of Oral and Oropharyngeal Squamous Cell Carcinoma. (C) 2015 Published by Elsevier Ltd.

AB - Purpose: Optimum management of the N0 neck is unresolved in oral cancer. Sentinel node biopsy (SNB) can reliably detect microscopic lymph node metastasis. The object of this study was to establish whether the technique was both reliable in staging the N0 neck and a safe oncological procedure in patients with early-stage oral squamous cell carcinoma. Methods: An European Organisation for Research and Treatment of Cancer-approved prospective, observational study commenced in 2005. Fourteen European centres recruited 415 patients with radiologically staged T1-T2N0 squamous cell carcinoma. SNB was undertaken with an average of 3.2 nodes removed per patient. Patients were excluded if the sentinel node (SN) could not be identified. A positive SN led to a neck dissection within 3 weeks. Analysis was performed at 3-year follow-up. Results: An SN was found in 99.5% of cases. Positive SNs were found in 23% (94 in 415). A false-negative result occurred in 14% (15 in 109) of patients, of whom eight were subsequently rescued by salvage therapy. Recurrence after a positive SNB and subsequent neck dissection occurred in 22 patients, of which 16 (73%) were in the neck and just six patients were rescued. Only minor complications (3%) were reported following SNB. Disease-specific survival was 94%. The sensitivity of SNB was 86% and the negative predictive value 95%. Conclusion: These data show that SNB is a reliable and safe oncological technique for staging the clinically N0 neck in patients with T1 and T2 oral cancer. EORTC Protocol 24021: Sentinel Node Biopsy in the Management of Oral and Oropharyngeal Squamous Cell Carcinoma. (C) 2015 Published by Elsevier Ltd.

KW - Oral Cancer Sentinel lymph node biopsy Metastasis Recurrence Micrometastasis Lymphoscintigraphy SQUAMOUS-CELL CARCINOMA LYMPH-NODE NECK DISSECTION MULTICENTER TRIAL HEAD METASTASES SURVIVAL CAVITY METAANALYSIS IMPACT

U2 - 10.1016/j.ejca.2015.08.023

DO - 10.1016/j.ejca.2015.08.023

M3 - Journal article

VL - 51

SP - 2777

EP - 2784

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 18

ER -